Literature DB >> 9409302

Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study.

A F Vuorio1, H Turtola, K M Piilahti, P Repo, T Kanninen, K Kontula.   

Abstract

A specific mutation termed FH-North Karelia [FH-NK] accounts for almost 90% of familial hypercholesterolemia [FH] cases in the Finnish North Karelia, with a population of about 180,000. Extensive search for its presence in the entire North Karelia province revealed 340 carriers of this mutation. Other mutations of the LDL receptor [LDLR] gene accounted for 67 cases of heterozygous FH. This gives a minimum FH prevalence of 1 in 441 inhabitants in North Karelia, with the highest density of patients in the Polvijärvi commune (1 in 143 inhabitants). Old parish records, confirmation records, and tax records were used to track a common ancestor for most of the present-day North Karelian FH-NK patients in the village of Puso, located within an area where the FH prevalence today is the highest. DNA analysis indicated that 2% of the subjects aged 1 to 25 years would have been diagnosed as false-negative and 7% as false-positive FH patients on the basis of LDL cholesterol [LDL-C] determinations alone. Common genetic variations of apolipoprotein E [apoE], XbaI, polymorphism of apolipoprotein B [apoB], and PvuII polymorphism of the intact LDLR allele contributed little to serum lipid variation in established carriers of the FH-NK allele, although apoE2/4 genotype and the presence of the PvuII restriction site tended to be associated with relatively low LDL-C levels. Coronary heart disease (CHD) was present in 65 (30%) out of the 179 FH gene carriers aged > or = 25 years, and 19 individuals had a previous history of acute myocardial infarction (AMI). The average age (mean +/- SD) at onset of CHD was 42 +/- 7 years for males and 48 +/- 11 years for females (P < .05). In stepwise logistic regression analysis carried out in carriers of the FH-NK allele, age, gender, smoking, and apoE allele E2 all emerged as independent determinants of risk of CHD or AMI. It may be concluded that the relatively high prevalence of FH patients in North Karelia province provides a unique founder population in which genetic and nongenetic factors modifying the course of FH can be effectively investigated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409302     DOI: 10.1161/01.atv.17.11.3127

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  20 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.

Authors:  E J Sijbrands; R G Westendorp; J C Defesche; P H de Meier; A H Smelt; J J Kastelein
Journal:  BMJ       Date:  2001-04-28

Review 3.  Clinical utility gene card for: hyperlipoproteinemia, TYPE II.

Authors:  Ursula Kassner; Marion Wühle-Demuth; Isabelle Missala; Steve E Humphries; Elisabeth Steinhagen-Thiessen; Ilja Demuth
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

4.  Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland.

Authors:  U Hodgson; T Laitinen; P Tukiainen
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

5.  Molecular characterization of Iranian patients with possible familial hypercholesterolemia.

Authors:  E Farrokhi; F Shayesteh; S Asadi Mobarakeh; F Roghani Dehkordi; K Ghatreh Samani; M Hashemzadeh Chaleshtori
Journal:  Indian J Clin Biochem       Date:  2011-02-10

Review 6.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

7.  Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice.

Authors:  Marcia L E MacDonald; Roshni R Singaraja; Nagat Bissada; Piers Ruddle; Russell Watts; Joanna M Karasinska; William T Gibson; Catherine Fievet; Jean E Vance; Bart Staels; Michael R Hayden
Journal:  J Lipid Res       Date:  2007-10-24       Impact factor: 5.922

8.  Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

Authors:  H A W Neil; V Seagroatt; D J Betteridge; M P Cooper; P N Durrington; J P Miller; M Seed; R P Naoumova; G R Thompson; R Huxley; S E Humphries
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

9.  Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes.

Authors:  D M Kusters; R Huijgen; J C Defesche; M N Vissers; I Kindt; B A Hutten; J J P Kastelein
Journal:  Neth Heart J       Date:  2011-01-27       Impact factor: 2.380

10.  Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations.

Authors:  K Widhalm; A Dirisamer; A Lindemayr; G Kostner
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.